Ramucirumab in combination with paclitaxel improves overall survival in second line treatment for metastatic gastric cancer

A randomised, international phase III RAINBOW study met its primary endpoint of improved overall survival with a monoclonal antibody ramucirumab when given in combination with paclitaxel as second-line treatment for metastatic gastric cancer. Median overall survival for patients receiving ramucirumab plus paclitaxel was 9.6 months, compared to 7.4 months for those receiving only paclitaxel. The study results were presented by Dr Hansjochen Wilke of the Kliniken Essen-Mitte, Essen, Germany at 2014 Gastrointestinal Cancer Symposium (16-18 January, San Francisco, USA). Read more here.